- Prospective Evaluation of AI-ECG for SHD Detection — Recruiting • Cardiology / Cardiovascular • NCT07057466.
- Sponsor: Imperial College London.
Verify eligibility, endpoints and current status on the original source registry before acting on this summary.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
AI-ECG-SHD is a multicentre prospective observational diagnostic accuracy study evaluating artificial intelligence-enhanced electrocardiography (AI-ECG) for the detection of structural heart disease in adults undergoing clinically indicated transthoracic echocardiography (TTE). Participants undergo standard 12-lead ECG acquisition together with ECG recordings obtained using portable or wearable single-, 3-, and 6-lead devices. Established AI-ECG models will be evaluated for the detection of heart failure, pulmonary hypertension and valvular heart disease using TTE as the clinical reference standard, with performance compared across ECG acquisition modalities within the same prospective cohort. AI-ECG predictions are generated…
- * Patients awaiting a transthoracic echocardiogram (TTE) based on clinical grounds as part of their standard care * Age 18-90 years * Able to provide informed consent
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.